JP2023522177A5 - - Google Patents

Info

Publication number
JP2023522177A5
JP2023522177A5 JP2022561449A JP2022561449A JP2023522177A5 JP 2023522177 A5 JP2023522177 A5 JP 2023522177A5 JP 2022561449 A JP2022561449 A JP 2022561449A JP 2022561449 A JP2022561449 A JP 2022561449A JP 2023522177 A5 JP2023522177 A5 JP 2023522177A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
carbon atom
group
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022561449A
Other languages
English (en)
Japanese (ja)
Other versions
JP7799618B2 (ja
JP2023522177A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/026316 external-priority patent/WO2021207453A1/en
Publication of JP2023522177A publication Critical patent/JP2023522177A/ja
Publication of JP2023522177A5 publication Critical patent/JP2023522177A5/ja
Application granted granted Critical
Publication of JP7799618B2 publication Critical patent/JP7799618B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022561449A 2020-04-09 2021-04-08 ハンチントン病を処置するための化合物 Active JP7799618B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063007660P 2020-04-09 2020-04-09
US202063007650P 2020-04-09 2020-04-09
US63/007,660 2020-04-09
US63/007,650 2020-04-09
PCT/US2021/026316 WO2021207453A1 (en) 2020-04-09 2021-04-08 Compounds for treating huntington's disease

Publications (3)

Publication Number Publication Date
JP2023522177A JP2023522177A (ja) 2023-05-29
JP2023522177A5 true JP2023522177A5 (cg-RX-API-DMAC7.html) 2024-04-18
JP7799618B2 JP7799618B2 (ja) 2026-01-15

Family

ID=75747091

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022561449A Active JP7799618B2 (ja) 2020-04-09 2021-04-08 ハンチントン病を処置するための化合物

Country Status (11)

Country Link
US (1) US20230234942A1 (cg-RX-API-DMAC7.html)
EP (1) EP4132923A1 (cg-RX-API-DMAC7.html)
JP (1) JP7799618B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230009367A (cg-RX-API-DMAC7.html)
CN (1) CN115768762A (cg-RX-API-DMAC7.html)
AU (1) AU2021254418A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022020147A2 (cg-RX-API-DMAC7.html)
CA (1) CA3173903A1 (cg-RX-API-DMAC7.html)
IL (1) IL297044A (cg-RX-API-DMAC7.html)
MX (1) MX2022012575A (cg-RX-API-DMAC7.html)
WO (1) WO2021207453A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4151627A1 (en) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
CA3139821A1 (en) * 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
WO2021231571A1 (en) 2020-05-13 2021-11-18 Chdi Foundation, Inc. Htt modulators for treating huntington's disease
AU2022394333A1 (en) 2021-11-17 2024-06-27 Chdi Foundation, Inc. HTT modulators for treating Huntington’s disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8729263B2 (en) * 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
CA3119019C (en) * 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
BR112020019373A2 (pt) * 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
IL279688B2 (en) * 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
CA3139821A1 (en) * 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease

Similar Documents

Publication Publication Date Title
RU2353616C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
RU2375363C2 (ru) Пирролотриазиновые производные анилина, полезные в качестве ингибиторов киназы
RU2336275C2 (ru) Пиримидопроизводные, характеризующиеся антипролиферативной активностью, и фармацевтическая композиция
TWI579284B (zh) 咪唑并吡咯啶酮化合物
RU2350605C2 (ru) Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ
CN114401952A (zh) 作为整合应激通路的调节剂的被取代的环烷基化合物
JP2023520925A5 (cg-RX-API-DMAC7.html)
JP2015501833A5 (cg-RX-API-DMAC7.html)
JP2009538910A5 (cg-RX-API-DMAC7.html)
JP2010536887A5 (cg-RX-API-DMAC7.html)
JP2019510787A5 (cg-RX-API-DMAC7.html)
JP2005538100A5 (cg-RX-API-DMAC7.html)
RU2014152790A (ru) Пирролопиразоновые ингибиторы танкиразы
JP2011509309A5 (cg-RX-API-DMAC7.html)
JP2011500758A5 (cg-RX-API-DMAC7.html)
CA2422354A1 (en) Pyrazole compounds useful as protein kinase inhibitors
JP2010523522A5 (cg-RX-API-DMAC7.html)
JP2004529140A5 (cg-RX-API-DMAC7.html)
JP2021502387A5 (cg-RX-API-DMAC7.html)
JP2010510999A5 (cg-RX-API-DMAC7.html)
JP2015504067A5 (cg-RX-API-DMAC7.html)
JP2002543185A5 (cg-RX-API-DMAC7.html)
JP2013542261A5 (cg-RX-API-DMAC7.html)
RU2002130252A (ru) Замещенные амиды бензойной кислоты и их применение для подавления ангиогенеза
RU2009139915A (ru) Производные имидазолидинона